Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library
Imunofan (RDKVYR): what the evidence says
At a glance
What it is: a synthetic hexapeptide (Arg-α-Asp-Lys-Val-Tyr-Arg) designed by modifying thymopoietin residues 32–37 and marketed in Russia as an immunomodulator. R1, R2 Nova's spec calls it a "bursopoietin hexapeptide"; the sources we read describe it as a thymopoietin derivative. UNVERIFIED the bursopoietin label.
What the evidence says: a small Russian randomized study in diabetic foot syndrome reported better results with Imunofan added to standard care. R3 Lab work shows it speeds skin-cell growth. R2
Biggest risks: unknown; no systematic safety data found.
Rating
| Human Human evidence | Limited: small Russian studies R3 |
| Animal Animal / lab evidence | Skin-cell and wound models R2 |
| Regulatory | Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page R4, R5, R6 · not named by WADA R7 |
| Established human dose | No |
Evidence verdict: Immune or infection adjunct: Limited (small Russian studies) · Wound repair: lab only
This page reports what studies used. It is not dosing advice.
Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source
About the evidence: the human data are a few small, regional studies. No Western randomized trial was found.
What is it?
Related pages: Thymopentin, Thymogen, Thymalin, Crystagen.
Does it work?
- Human Diabetic foot (n = 69): higher therapeutic effectiveness than standard care alone. R3
- Human Other infection/cancer uses: described in a Russian review without controlled data. R1
- Animal Wound repair: stimulated skin-cell proliferation in lab studies. R2
Is it safe?
- Unknown No systematic human safety data found.
Gray-market vials: extra risks
A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe.
Is it legal?
- US: not FDA-approved; no Drugs@FDA application found (openFDA searched Oct 26, 2026).
- Compounding: not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page. R4, R5, R6
- Sport: not named on WADA's 2026 Prohibited List. R7
Study details
Study details
These are amounts researchers used, not recommendations.
| Study | People / model | Route | Amount used | Follow-up | Reported | Citation |
|---|---|---|---|---|---|---|
| Tutel'ian 2009 | 69 T2D with diabetic foot | Injection | Per study | Per study | Better than basic therapy alone | PMID 20481041 |
Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 26, 2026)
- R1 Lebedev VV, et al. Vestn Ross Akad Med Nauk. 1999. PMID 10377887
- R2 Sawicka J, et al. Molecules. 2020. PMID 32585846
- R3 Tutel'ian AV, et al. Ter Arkh. 2009. PMID 20481041
- R4 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
- R5 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
- R6 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- R7 WADA. The 2026 Prohibited List, full list checked; compound not named. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
Disclaimer
This page is for education and harm reduction, not medical advice or a recommendation to use Imunofan (RDKVYR). This compound is not FDA-approved. Any product sold under this name in the US is unregulated. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).